A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee

PHASE3CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Osteoarthritis, Knee
Interventions
DRUG

Placebo

Healthcare professional-administered intra-articular injection of vehicle.

DRUG

Lorecivivint

Healthcare professional-administered intra-articular injections of lorecivivint.

Trial Locations (42)

10016

Research Site, New York

10530

Research Site, Hartsdale

14609

Research Site, Rochester

22911

Research Site, Charlottesville

27103

Research Site, Winston-Salem

28144

Research Site, Salisbury

28209

Research Site, Charlotte

29464

Research Site, Mt. Pleasant

29707

Research Site, Fort Mill

30189

Research Site, Woodstock

30265

Research Site, Newnan

32127

Research Site, Port Orange

32789

Research Site, Winter Park

33014

Research Site, Miami Lakes

33016

Research Site, Hialeah

33173

Research Site, Miami

33409

Research Site, West Palm Beach

33880

Research Site, Winter Haven

43235

Research Site, Columbus

45242

Research Site, Cincinnati

46383

Research Site, Valparaiso

48085

Research Site, Troy

48706

Research Site, Bay City

57702

Research Site, Rapid City

60031

Research Site, Gurnee

60523

Research Site, Oak Brook

63042

Research Site, Hazelwood

63141

Research Site, St Louis

68114

Research Site, Omaha

70124

Research Site, New Orleans

73103

Research Site, Oklahoma City

75007

Research Site, Carrollton

75075

Research Site, Plano

78229

Research Site, San Antonio

80209

Research Site, Denver

84020

Research Site, Draper

84107

Research Site, Salt Lake City

85712

Research Site, Tucson

91360

Research Site, Thousand Oaks

91767

Research Site, Pomona

92103

Research Site, San Diego

92805

Research Site, Anaheim

Sponsors
All Listed Sponsors
lead

Biosplice Therapeutics, Inc.

INDUSTRY